| Software tools for model-informed precision dosing: how well do they satisfy the needs? W Kantasiripitak, R Van Daele, M Gijsen, M Ferrante, I Spriet, E Dreesen Frontiers in pharmacology 11, 620, 2020 | 108 | 2020 |
| A model-based tool for guiding infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases W Kantasiripitak, SG Wicha, D Thomas, I Hoffman, M Ferrante, S Vermeire, ... Journal of Crohn's and Colitis 17 (6), 896-908, 2023 | 23 | 2023 |
| Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases W Kantasiripitak, A Outtier, SG Wicha, A Kensert, Z Wang, J Sabino, ... CPT: pharmacometrics & systems pharmacology 11 (8), 1045-1059, 2022 | 23 | 2022 |
| A Population pharmacokinetic and exposure–response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis E Dreesen, W Kantasiripitak, I Detrez, S Stefanović, S Vermeire, ... Inflammatory Bowel Diseases 26 (4), 570-580, 2020 | 21 | 2020 |
| Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases W Kantasiripitak, Z Wang, I Spriet, M Ferrante, E Dreesen Expert Review of Clinical Pharmacology 14 (12), 1455-1466, 2021 | 19 | 2021 |
| The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases W Kantasiripitak, B Verstockt, D Alsoud, T Lobaton, D Thomas, A Gils, ... British Journal of Clinical Pharmacology 87 (10), 3776-3789, 2021 | 13 | 2021 |
| DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease Z Wang, W Kantasiripitak, B Verstockt, S Joao, M Ferrante, P Declerck, ... Journal of Crohn's and Colitis 16 (Supplement_1), i131-i132, 2022 | 1 | 2022 |
| P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis W Kantasiripitak, E Dreesen, I Detrez, S Stefanović, D Drobne, S Vermeire, ... Journal of Crohn's and Colitis 13 (Supplement_1), S409-S410, 2019 | 1 | 2019 |
| A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis W Kantasiripitak, E Dreesen, I Detrez, S Stefanovic, S Vermeire, ... Poster session presented at: annual meeting of the population approach group …, 2019 | 1 | 2019 |
| P0869 Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases Z Wang, I De Greef, W Kantasiripitak, SG Wicha, S Tops, M Nigro, ... Journal of Crohn's and Colitis 19 (Supplement_1), i1655-i1656, 2025 | | 2025 |
| OP12 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s disease Z Wang, Y Hoffert, W Zhang, W Kantasiripitak, B Verstockt, J Sabino, ... Journal of Crohn's and Colitis 19 (Supplement_1), i24-i26, 2025 | | 2025 |
| Model-Informed Dosing Interval Extension of Infliximab in Patients With Inflammatory Bowel Diseases: Six Months Interim Analysis of the MODIFI Trial Z Wang, I De Greef, W Kantasiripitak, SG Wicha, S Tops, M Nigro, ... American Journal Of Gastroenterology 119 (10S), S855-S856, 2024 | | 2024 |
| S1204 Model-Informed Dosing Interval Extension of Infliximab in Patients With Inflammatory Bowel Diseases: Six Months Interim Analysis of the MODIFI Trial Z Wang, I De Greef, W Kantasiripitak, SG Wicha, S Tops, M Nigro, ... Official journal of the American College of Gastroenterology| ACG 119 (10S …, 2024 | | 2024 |
| Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases W Kantasiripitak, E Dreesen, M Ferrante, D Thomas | | 2023 |
| P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval W Kantasiripitak, A Outtier, D Thomas, J Sabino, S Vermeire, M Ferrante, ... Journal of Crohn's and Colitis 17 (Supplement_1), i833-i834, 2023 | | 2023 |
| P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases W Kantasiripitak, A Outtier, D Thomas, J Sabino, S Vermeire, M Ferrante, ... Journal of Crohn's and Colitis 16 (Supplement_1), i485-i486, 2022 | | 2022 |
| P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach W Kantasiripitak, A Outtier, D Thomas, A Kensert, Z Wang, J Sabino, ... Journal of Crohn's and Colitis 16 (Supplement_1), i350-i351, 2022 | | 2022 |
| Su438 THE EFFECT OF AGING ON INFLIXIMAB EXPOSURE AND RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES W Kantasiripitak, B Verstockt, D Alsoud, T Lobaton, D Thomas, A Gils, ... Gastroenterology 160 (6), S-689, 2021 | | 2021 |
| P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn’s disease W Kantasiripitak, R Mathôt, B Oldenburg, A Buisson, M Ferrante, ... Journal of Crohn's and Colitis 15 (Supplement_1), S481-S483, 2021 | | 2021 |
| P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases W Kantasiripitak, K van Hoeve, J Sabino, S Vermeire, I Hoffman, ... Journal of Crohn's and Colitis 15 (Supplement_1), S332-S333, 2021 | | 2021 |
